Smith & Nephew lance sa nouvelle gamme de produits ALLEVYN* ? la conf?rence European Customer Conference

Cette gamme de produits permet aux professionnels de la santé de réduire la douleur et de combattre les infections.


Hull, (Royaume-Uni), le 12 décembre 2007

La division Advanced Wound Management (traitement avancé des plaies) de Smith & Nephew (LSE: SN; NYSE:SNN) a lancé sa nouvelle gamme de produits ALLEVYN* lors d'une conférence exclusive à Londres ce week-end et a présenté les avantages de cette dernière à plus de 250 professionnels de la santé européens.

Cette conférence a réuni des clients de toute l'Europe qui ont pu s'intéresser à la gamme spécifique de produits ALLEVYN récemment enrichie, qui offre toujours la "meilleure voie vers la guérison" et qui désormais traite les problèmes de douleurs et d'infections.

Following the successful launch of ALLEVYN Ag in October 2007, an additional two new products have been added to the product range, ALLEVYN Gentle and ALLEVYN Gentle Border. The ALLEVYN product range further expands the healthcare professionalsŽ capacity to help fight infection, minimise pain, maximise patient comfort and optimise healing for patients in more situations.

Chaired by Professor Aidan Halligan, former Deputy Chief Medical Officer and Director of Clinical Governance for the NHS and now Chief Executive Officer of Ellison Health Ltd, the conference covered everything from understanding some of the key issues in todayŽs woundcare, such as quality of life and managing infection to the science behind the ALLEVYN range and its relation to clinical practice, as well as a full introduction to the new products in the ALLEVYN range. Attendees also heard from a range of clinical professionals from across Europe on their experiences of managing wounds and removing barriers to healing with ALLEVYN.

Professor Halligan commented on the conference, "This conference succeeded in reawakening the attending European Healthcare professionalŽs collective passion for patient care, a fundamental principle of overall successful wound care. The diversity of the conference included everything from authentic patient perspectives of living with life threatening wounds, all the way to improving quality of life in palliative care."

Donna OŽShea from the Tissue Viability Team at Cornwall and Isle of Scilly Primary Care Trust, said about the conference, "Inspirational values and personal experiences shared from and with many European colleagues made this an exciting and interesting launch of products delivered with realism and passion."

Enquiries
Sidonie Myers
Head of Communication
Smith & Nephew Advanced Wound Management
Tel: +44 (0) 1482 673246

Notes for Editors

ALLEVYN now further simplifies customer choice, by providing a new, unique and powerful combination of benefits through each of the four product groups in its newly defined and extended range. ALLEVYN has now combined the proven strengths of its triple-action ALLEVYN technology with a new level of versatility and breadth of application.

The three new products in the range are:

ALLEVYN Ag - All the benefits of ALLEVYN, with the addition of anti-microbial silver for use on wounds with suspected infection or infected wounds treated as per local protocol.

ALLEVYN Gentle Border - All the benefits of ALLEVYN with the addition of a silicone gel adhesive for use on patients with fragile skin where secondary retention is not used.

ALLEVYN Gentle - All the benefits of ALLEVYN with the addition of a soft gel adhesive for use on patients with fragile skin when secondary retention is required

About Smith & Nephew

Smith & Nephew Advanced Wound Management is headquartered in the United Kingdom. The organisation has manufacturing centres in the United Kingdom and Largo, FL.

Smith & Nephew is a global medical technology business, specialising in Orthopaedic Reconstruction, Orthopaedic Trauma and Clinical Therapies, Endoscopy and Advanced Wound Management products. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve peopleŽs lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2006 were nearly $2.8 billion.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & NephewŽs most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & NephewŽs expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

* Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

This information is provided by RNS
The company news service from the London Stock Exchange



Copyright Hugin